SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026

BCRX

BioCryst Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 18h ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor for any competitive shifts in HAE prophylaxis market share based on real-world evidence; navenibart interim results may influence pipeline valuation if positive.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

BCRX drug pipeline →

navenibart

◆ Mixed Named in this press release
Impact
Phase
Phase 3
Time to market
Assuming positive Phase 3 data (Q3 2027), a US regulatory filing would follow around end-2027, with potential approval in 2028-2029.
Next catalyst
None dated

What to watchNavenibart is a promising long-term pipeline story within BioCryst, but there is no imminent binary catalyst for ~12+ months. Investors should watch for interim data updates at medical conferences and the pivotal Phase 3 ALPHA-ORBIT readout in Q3 2027. In the meantime, near-term BCRX value is driven by ORLADEYO commercial execution and the ongoing business restructuring.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$7.61
T+0 close · Nov 13, 2026 · via day close
Latest settled
−2.10%
T+1 · $7.45
Vs SPY
−0.19%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $7.61entry
  2. T+1 · 20h ago −2.10%α −0.19% · $7.45
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioCryst presented two real-world studies at ACAAI 2026 showing that ORLADEYO (berotralstat) reduces hospitalizations and emergency department visits in HAE patients, both in treatment-naïve initiators and in patients switching from another prophylactic therapy. The data support ORLADEYO's clinical and economic profile but are not a regulatory or commercial catalyst.

Key Facts

  • ORLADEYO is the first and only targeted oral prophylactic therapy for HAE in patients aged 2 and older.
  • Study 1 (n=78): Patients switching to ORLADEYO from another LTP saw a 30% reduction in overall angioedema-related visits (p=0.039) and a 30% reduction in outpatient/ED visits (p=0.040).
  • Study 2 (n=128 ORLADEYO, n=236 lanadelumab, n=95 SC-pdC1-INH): All cohorts had statistically significant reductions in ED visits; ORLADEYO showed a 53% reduction in all-cause hospitalizations and a 61% reduction in angioedema-related ED visits.
  • No statistically significant differences in magnitude of reductions were observed between ORLADEYO and lanadelumab or SC-pdC1-INH.
  • BioCryst also presented interim data on navenibart (investigational monoclonal antibody) with potential best-in-class dosing every 3 or 6 months.

Financial Impact

No financial figures provided; real-world data may support ORLADEYO's market positioning but no revenue or guidance impact stated.

Risk Factors

  • Real-world data are observational and may not reflect controlled trial outcomes.
  • No statistically significant differentiation from lanadelumab or SC-pdC1-INH could limit commercial advantage.
  • Navenibart is investigational; clinical development risks remain.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402489

Track record

20 reports on BCRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
  2. Nov 13, 20263d ago Press Release Neutral 3/10 Viewing Entry $7.61 Now $7.45 −2.10% settles Feb 11
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
  4. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
  8. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
  9. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
  10. Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026